InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$238.97

2026-10-16

Market Cap

$33.6B

Volume

2.5M

52-Wk High

$277.67

52-Wk Low

$180.27

Trailing PE

22.9

P/S

5.94

Gross Margin

61.2%

Net Margin

26.9%

ROE

24%

ROIC

19%

Piotroski

6/9

Altman Z

11.3

1-Yr Return

-11.3%

5-Yr Return

+86.4%

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

SectorHealthcareIndustryMedical - Instruments & SuppliesExchangeNYSEMarket Cap$33.6BEmployees11,370 (SEC-filed)CEOMichael J. FarrellIPO1995-06-02CountryUS

9001 Spectrum Center Boulevard, San Diego, CA 92123 · Tel 858 836 5000 · resmed.com

INSIDERSTREET SCORE82 / 100Street mean $252.43 (7 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$12M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · RMD -11.3% · S&P 500 +15.9% · spread -27.2pp

7 Years vs S&P 500 · RMD +86.4% · S&P 500 +189.9% · spread -103.5pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE82of 100

Score Breakdown

Profitability	93/100
Growth	55/100
Momentum	81/100
Quality	93/100
Earnings Quality	44/100
Balance Sheet	91/100
Value	63/100
Risk (safety)	100/100
Overall	81.9/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MDLN	43
WST	72
BDX	43
HOLX	56
SOLV	37
BAX	32
RMD	82

IS Score Trend — quarterly

16 quarters, 23 Q1 to 26 Q4. Peak 85 in 25 Q3, latest 82 — -3 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY82 / 100IS Score 81.9 / 100 · -3.2 from peak of 85

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 80 / 100 · Power +60 · 19 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 82 and price structure at 80 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 81.9	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 85 → 83 → 82 → 82	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 950 → now 892	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)3 buys2026-09-11

Insider Buys (180d)0none disclosed

ETF Funds (30d)1066 up / 886 downnet +180 funds

Institutions Added (13F)-51managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 950 · latest 892 (-58 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	892	101.2M	$19.4B	69.9%
2026 Q1	943	97.7M	$21.6B	67.5%
2025 Q4	948	97.0M	$23.0B	67.1%
2025 Q3	950	91.9M	$24.8B	63.5%
2025 Q2	923	92.8M	$23.8B	64.1%
2025 Q1	887	94.4M	$21.0B	65.2%
2024 Q4	872	90.6M	$20.6B	62.6%
2024 Q3	804	87.3M	$21.1B	60.4%
2024 Q2	775	85.9M	$16.3B	59.4%
2024 Q1	721	83.4M	$16.4B	57.6%
2023 Q4	691	81.2M	$13.9B	56.1%
2023 Q3	660	88.1M	$12.9B	60.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Farrell Michael J.	director, Chairman and CEO	2026-10-07	EXERCISE	4,991	$0.73M	484,794
Farrell Michael J.	director, Chairman and CEO	2026-10-07	SELL	4,991	$1.13M	479,803
Farrell Michael J.	director, Chairman and CEO	2026-10-07	EXERCISE	4,991	$0.73M	4,993
Farrell Michael J.	director, Chairman and CEO	2026-09-08	EXERCISE	4,991	$0.73M	471,247
Farrell Michael J.	director, Chairman and CEO	2026-09-08	SELL	4,991	$1.11M	466,256
Farrell Michael J.	director, Chairman and CEO	2026-09-08	EXERCISE	4,991	$0.73M	9,984
Farrell Peter C	director	2026-09-02	SELL	970	$0.23M	51,803
Bloomer Aaron	Chief Financial Officer	2026-08-14	A-Award	9,072	—	9,072

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	14	54,898	$12.2M	Counted
M — Exercises (paired A/D)	8	39,928	$5.8M	None — mechanics
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$12.2M14 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-11	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-05-01	2026-06-11
Ro Khanna	House	BUY	$1,001 - $15,000	2026-04-13	2026-05-13
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-21
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-14
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-13

House 12-Mo4 trades3 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

13F Filers (last complete Q)943

13F Shares98M67.5% of shares out

New / Closed106 / 95positions, QoQ

Increased / Reduced364 / 320positions, QoQ

Put/Call (13F)1.19option positions

Free Float99.1%139M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	105,445	$23M
Confluence Investment Management L	84,518	$19M
Massmutual Private Wealth & Trust,	63,623	$14M
Northcrest Asset Manangement, Llc	43,686	$10M
Addenda Capital Inc.	42,604	$9M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$1.0B
VTSAX	0.0%	$1.0B
VSMPX	0.0%	$1.0B
VTI	0.0%	$1.0B
VOO	0.0%	$838M
VFIAX	0.0%	$838M

13F Filers Holding RMD — quarterly

Institutional Put/Call — quarterly

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session75.5%2026-10-15

20-Day Avg67.5%50-day 73.8%

TrendFalling20d vs 50d

By Market CenterQ: 75% · N: 81% · B: 55%latest session

Weekly Notional ($B)

Where RMD Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.3M	22 sh
Ubsa Ubs Ats	1.3M	29 sh
Ebxl Level Ats	0.9M	15 sh
Sgmt Sigma X2	0.8M	23 sh
Mstx Ms Trajectory Cross (Ats-1)	0.8M	24 sh
Mlix Instinct X	0.6M	34 sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Where a dollar of ResMed Inc. revenue goes. All values FY2026 filings, live.

Region	Revenue	Share
U [S]	$3.0B	64%
Global	$1.7B	36%

RMD (live moat model)Peer median: MDLN · WST · BDX · HOLX · SOLV

Component scores from the live moat model. Peer median illustrative.

Moat score 77/100 — Wide; primary source Efficient Scale.

3.8 · Employees (SEC filings)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Officer	Title
Michael J. Farrell	Chief Executive Officer & Chairman
Justin Leong	Chief Product Officer
Brett A. Sandercock	Advisor
Michael Rider	Chief Legal Officer & Secretary

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)3 of 6recent quarters

Avg Surprise+1.3%

Next Report2026-10-29

Income Quality1.19OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY22	FY23	FY24	FY25	FY26
Revenue	+11.9%	+18.0%	+10.9%	+9.8%	+9.9%
Gross profit	+10.1%	+16.4%	+12.7%	+15.1%	+13.0%
Operating income	+10.7%	+13.2%	+16.6%	+27.7%	+13.2%
Net income	+64.3%	+15.2%	+13.7%	+37.2%	+8.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

$B · FY ends	FY22	FY23	FY24	FY25	FY26
Revenue	3.6	4.2	4.7	5.1	5.7
Cost of revenue	1.6	1.9	2.0	2.1	2.2
Gross profit	2.0	2.4	2.7	3.1	3.5
R&D expense	0.3	0.3	0.3	0.3	0.4
SG&A expense	0.7	0.9	0.9	1.0	1.1
Operating income	1.0	1.1	1.3	1.7	1.9
EBITDA	1.2	1.4	1.5	1.9	2.2
D&A	0.2	0.2	0.2	0.2	0.2
Pretax income	1.0	1.1	1.3	1.7	1.9
Income tax	0.2	0.2	0.2	0.3	0.4
Net income	0.8	0.9	1.0	1.4	1.5
Diluted EPS ($)	5.30	6.09	6.92	9.51	10.40
Diluted shares (M)	147	147	148	147	145

Operating CF$2B

CapEx$0B

Free cash flow$2B

SBC$0B

Buybacks$1B

Net cash change$0B

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY23	FY24	FY25	FY26
Cash & equivalents	0.2	0.2	1.2	1.5
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	0.7	0.8	1.0	1.0
Total current assets	2.4	2.4	3.5	4.3
PP&E (net)	0.7	0.7	0.7	0.7
Goodwill + intangibles	3.3	3.3	3.5	3.4
Total assets	6.8	6.9	8.2	9.0
Accounts payable	0.2	0.2	0.3	0.3
Short-term debt	0.0	0.0	0.0	0.3
Deferred revenue	0.1	0.2	0.2	0.2
Total current liabilities	0.8	0.9	1.0	1.4
Long-term debt	1.4	0.7	0.7	0.4
Total liabilities	2.6	2.0	2.2	2.4
Shareholders' equity	4.1	4.9	6.0	6.6

Cash Flow Statement — Full

$B	FY23	FY24	FY25	FY26
Net income	0.9	1.0	1.4	1.5
D&A	0.2	0.2	0.2	0.2
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	(0.5)	0.0	0.0	(0.1)
Operating cash flow	0.7	1.4	1.8	1.8
Capital expenditures	(0.1)	(0.1)	(0.1)	(0.2)
Investing cash flow	(1.2)	(0.3)	(0.2)	(0.5)
Buybacks	0.0	(0.2)	(0.3)	(0.7)
Dividends paid	(0.3)	(0.3)	(0.3)	(0.3)
Debt issuance / (repay)	0.7	(0.7)	(0.0)	(0.0)
Financing cash flow	0.4	(1.1)	(0.6)	(1.0)
Free cash flow	0.6	1.3	1.7	1.6

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
PROFITABILITY
ROE	25.0%	24.0%	22.7%	25.9%	24.3%	24%
ROA	15.9%	15.2%	15.0%	18.6%	17.8%	17.0%
ROIC	20.3%	16.8%	19.4%	25.1%	25.3%	19.1%
Gross margin	56.6%	55.8%	56.7%	59.4%	61.1%	61.2%
Operating margin	28.0%	26.8%	28.2%	32.7%	33.8%	33.5%
Net margin	21.8%	21.3%	21.8%	27.2%	26.9%	26.9%
EBITDA margin	32.9%	32.2%	32.7%	37.2%	38.1%	38.3%
FCF margin	5.5%	13.2%	27.5%	32.2%	51.1%	—
VALUATION
P/E	38.30	35.07	27.29	26.96	18.55	22.9
P/B	8.88	7.62	5.73	6.33	4.29	5.3
P/S	8.34	7.45	5.95	7.34	5.00	5.94
P/FCF	153.00	56.28	21.66	22.77	9.78	11.6
EV/EBITDA	25.54	24.34	18.67	19.45	12.80	15.2
EV/Revenue	8.52	7.77	6.08	7.27	4.88	5.8
Earnings yield	2.6%	2.9%	3.7%	3.7%	5.4%	4.41%
FCF yield	0.7%	1.8%	4.6%	4.4%	10.2%	8.60%

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
LEVERAGE & SOLVENCY
Current ratio	2.80	3.12	2.59	3.44	3.10	3.10
Quick ratio	1.72	1.81	1.69	2.53	2.42	2.42
Debt / equity	0.27	0.38	0.18	0.14	0.13	0.13
Debt / assets	18.0%	23.4%	12.7%	10.4%	9.2%	9.2%
Net debt / EBITDA	0.54	1.00	0.42	-0.19	-0.30	-0.30
Interest coverage	44.83	24.30	24.87	125.28	66.24	—

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
EFFICIENCY
Asset turnover	0.73	0.71	0.69	0.68	0.66	0.63
Receivables turnover	6.01	6.59	6.08	5.79	5.72	5.5
DSO (days)	61	55	60	63	64	67
DPO (days)	35	30	35	45	49	51
Cash conversion cycle	167	195	187	171	171	173
GROWTH (YoY)
Revenue growth	11.9%	18.0%	10.9%	9.8%	9.9%	—
Net income growth	64.3%	15.2%	13.7%	37.2%	8.8%	—
EPS growth	63.8%	14.7%	13.8%	37.7%	10.3%	—
FCF growth	-68.5%	186.7%	130.0%	28.9%	74.2%	—
PER SHARE ($)
EPS (diluted, TTM)	5.30	6.08	6.92	9.53	10.51	10.53
Book value / share	22.86	27.99	32.97	40.59	45.42	45.51
Revenue / share	24.34	28.62	31.76	35.00	39.00	39.07
FCF / share	1.33	3.79	8.72	11.28	19.93	19.97
Cash / share	1.86	1.54	1.62	8.23	10.13	10.15
SHAREHOLDER RETURN & SCORES
Buyback yield	0.0%	0.0%	0.5%	0.8%	4.2%	4.25%
Altman Z-Score	12.96	9.56	10.91	12.99	9.98	11.3
Piotroski F-Score	6	4	8	9	7	6/9
Beneish M-Score	-2.17	-2.00	-2.58	-2.55	-3.29	-3.29

Model	Score	Zone	Note
Piotroski F-Score	6 / 9	Middling
Altman Z-Score	11.3	Safe (>2.99)	Safe
Income quality	1.19	Cash-backed	OCF ÷ net income
Beneish M-Score	-3.29	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.79
Interest burden	1.00
Operating margin	34.0%
Asset turnover	0.66×
Financial leverage	1.37×
= ROE	24%

Growth Quality (live)	Value
Revenue stability	1.00
Earnings stability	0.97
Earnings persistence	0.96
Revenue CAGR 3y	10.2%
EPS CAGR 3y	20.0%
FCF CAGR 3y	72.9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield4.25%

Dividend Yield1.03%

Total Shareholder Return5.99%cash yield

SBC / Revenue3.2%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MDLN	$31.5B	41.8	3%	0.8%	—	4/9	-12.3%
WST	$27.0B	48.8	19%	17.7%	+12.4%	9/9	+43.8%
BDX	$52.2B	57.8	4%	7.6%	-2.6%	6/9	+4.0%
HOLX	$17.0B	30.3	11%	17.1%	+2.2%	6/9	+13.2%
SOLV	$14.6B	10.4	34%	4.2%	-0.9%	7/9	—
BAX	$13.1B	-12.4	-16%	4.3%	+5.4%	3/9	—
RGEN	$11.1B	237.1	2%	2.5%	+16.5%	8/9	—
AVTR	$11.1B	-19.6	-10%	2.3%	-1.6%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

35 Analysts

Str Sell (0)Sell (5)Hold (16)Buy (14)Str Buy (0)

Mean Target (qtr)$252.437 targets

Target vs. Price+5.6%last-quarter mean

Next Report2026-10-29street $2.68

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$5.65B	$5.66B / $5.64B	$11.13	$11.23 / $11.08	8
FY2027	$5.81B	$6.04B / $5.76B	$12.10	$12.26 / $11.76	14
FY2028	$6.19B	$6.54B / $6.02B	$13.30	$13.65 / $13.11	14

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$240.00	+0.4%	1
Last Quarter	$252.43	+5.6%	7
Last Year	$266.83	+11.7%	29
All Time	$256.71	+7.4%	48

Rolling mean of published targets vs. last close $238.97. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A

DCF

5/5

ROE

5/5

ROA

5/5

Debt/Eq

3/5

P/E

3/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

RMD -11.3% vs S&P 500 +15.9% — spread -27.2pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$226.51	+12.46	+5.50%	Above
SMA 50	$226.86	+12.11	+5.34%	Above
SMA 200	$224.89	+14.08	+6.26%	Above
EMA 9	$233.59	+5.38	+2.30%	Above
EMA 21	$229.21	+9.76	+4.26%	Above
EMA 50	$224.70	+14.27	+6.35%	Above
EMA 200	$225.24	+13.73	+6.10%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6019 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%82

Volume 20%69

Volatility 10%100

Patterns 15%38

This Week100% bullishof 11 price-based votes

4 Weeks Ago27%+73 pts since

12 Weeks Ago9%+91 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$226.51

Price vs SMA 50$226.86

Price vs SMA 200$224.89

EMA 9/21 Cross233.6/229.2

SMA 50/200Golden

ADX DirectionADX 21

Supertrend$225

Parabolic SAR$224

SMA Slope0.700

RSI66.5

Stochastic K/D91/92

StochRSI K/D93/98

Williams %R-15

CCI163

TSI vs Signal22.1

CMO33.0

ROC9.17%

OBV SignalAccum

Chaikin MF-0.020

MFI70

Force Index1M

Elder Ray Bull13.37

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 92

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$240.92 / $243.94 / $245.65	S1 / S2	$239.21 / $236.19
Bollinger (20,2)	$212.98 – $240.04	Squeeze	Off
52-wk range	$180.27 – $277.03	Off 52-wk high	-13.7%
ATR (14)	$5.35 (2.2%)	Historical vol	19.1%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.0%Jan65%

-0.7%Feb50%

+1.9%Mar67%

+1.4%Apr50%

+0.4%May65%

+2.3%Jun60%

+4.4%Jul80%

+0.5%Aug50%

-1.1%Sep35%

+1.1%Oct50%

+3.2%Nov80%

+1.3%Dec65%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	RMD	S&P 500
Weekly volatility (σ, 1y)	3.76%	1.83%
Best / worst week (1y)	+11.1% / -10.4%	—
Max drawdown (5y, monthly)	-51.3%	—
1-week VaR (95%)	-7.8%	—
Beta (5y)	0.77	1.00

RMD EQUITY WEATHER (LIVE)PARTLY CLOUDY · +27

Trend+46

Momentum+66

Volume+42

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 132 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+26.6+36.9 vs industry

Trend+46.1+45.3 vs industry

Momentum+65.6+66.7 vs industry

Volume+42.1+25.0 vs industry

Reading	RMD	Medical - Instruments & Supplies n=284	Healthcare n=5,272	All US symbols n=70,435
Overall	+26.6	-10.3	-24.0	-20.5
Trend	+46.1	+0.7	-25.6	-21.3
Momentum	+65.6	-1.1	-28.5	-15.8
Volume	+42.1	+17.1	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Michael Farrell Chief executive officer	$7.5M	88% equity+incentive
Rob Douglas President and chief operating of	$5.2M	48% equity+incentive
Brett Sandercock Chief financial officer	$2.5M	82% equity+incentive
Jim Hollingshead President – Americas	$2.4M	62% equity+incentive
David Pendarvis Chief administrative officer	$2.4M	61% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	65
Social	68
Governance	63
Composite ESG	65

Composite ESG Trend

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2021 to 2026
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-08-06
Analyst estimates	dim/forward_estimates	3 rows · 2026-06-30 to 2028-06-30
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	113 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-07 to 2026-10-07
Proposed sales (Form 144)	edgar/form144	not present for this symbol
Beneficial ownership (13D/G)	edgar/13dg	not present for this symbol
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

ResMed Inc. (RMD)

ResMed Inc. (RMD)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

ResMed Inc. (RMD)

Institutions holding — 12 quarters

ResMed Inc. (RMD)

Monthly Net Insider Flow (000 shares)

Signal Summary

ResMed Inc. (RMD)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding RMD — quarterly

Institutional Put/Call — quarterly

Where RMD Trades in the Dark

ResMed Inc. (RMD)

3.8 · Employees (SEC filings)

ResMed Inc. (RMD)

ResMed Inc. (RMD)

ResMed Inc. (RMD)

ResMed Inc. (RMD)

Balance Sheet — Full

Cash Flow Statement — Full

ResMed Inc. (RMD)

ResMed Inc. (RMD)

ResMed Inc. (RMD)

ResMed Inc. (RMD)

Street Price Target — Trajectory

Third-Party Composite Rating

ResMed Inc. (RMD)

ResMed Inc. (RMD)

Family Scores (site weights)

ResMed Inc. (RMD)

ResMed Inc. (RMD)

ResMed Inc. (RMD)